JP2021527051A - ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用 - Google Patents

ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用 Download PDF

Info

Publication number
JP2021527051A
JP2021527051A JP2020567845A JP2020567845A JP2021527051A JP 2021527051 A JP2021527051 A JP 2021527051A JP 2020567845 A JP2020567845 A JP 2020567845A JP 2020567845 A JP2020567845 A JP 2020567845A JP 2021527051 A JP2021527051 A JP 2021527051A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
och
nhc
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020567845A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019236631A5 (https=
JP2021527051A5 (https=
Inventor
ブイ，ミナ・エイチ・ティー
デュークス，エイドリアン・オー
ハン，シンピン
フー，デニス・エックス
ジャクソン，ジェフリー・ジェイ
コ，ユ・ミン
レジェ，ポール・アール
マー，アンチイ
マウン，ジャック
ン，アンドリュー・エイ
オカノ，アキノリ
ロブレス，オマール
シブヤ，グラント
シュナトナ，ハンター・ピー
シュワルツ，ジェイコブ・ビー
シャクーミン，アントン・エイ
ブストロ，デイビッド・ジェイ
ジビンスキー，ミハイル
Original Assignee
ラプト・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラプト・セラピューティクス・インコーポレイテッド filed Critical ラプト・セラピューティクス・インコーポレイテッド
Publication of JP2021527051A publication Critical patent/JP2021527051A/ja
Publication of JPWO2019236631A5 publication Critical patent/JPWO2019236631A5/ja
Publication of JP2021527051A5 publication Critical patent/JP2021527051A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020567845A 2018-06-05 2019-06-04 ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用 Pending JP2021527051A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862680891P 2018-06-05 2018-06-05
US62/680,891 2018-06-05
US201962831006P 2019-04-08 2019-04-08
US62/831,006 2019-04-08
PCT/US2019/035462 WO2019236631A1 (en) 2018-06-05 2019-06-04 Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses

Publications (3)

Publication Number Publication Date
JP2021527051A true JP2021527051A (ja) 2021-10-11
JPWO2019236631A5 JPWO2019236631A5 (https=) 2022-06-27
JP2021527051A5 JP2021527051A5 (https=) 2022-06-27

Family

ID=67185700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567845A Pending JP2021527051A (ja) 2018-06-05 2019-06-04 ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用

Country Status (5)

Country Link
US (1) US11046699B2 (https=)
EP (1) EP3802544A1 (https=)
JP (1) JP2021527051A (https=)
TW (1) TW202016112A (https=)
WO (1) WO2019236631A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499644B (zh) * 2020-04-24 2021-07-20 苏州大学 咪唑并[1,5-a]喹唑啉-5(4H)-酮类衍生物及其制备方法和用途
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
CN114516828A (zh) * 2020-11-19 2022-05-20 江苏威奇达药业有限公司 一种提高负氮杂提取率的提取工艺
US20250000859A1 (en) * 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
MX2024007328A (es) 2021-12-14 2024-09-30 Crossfire Oncology Holding B V Inhibidores macrociclicos de btk.
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors
CN116478145B (zh) * 2022-04-13 2024-02-02 杭州邦顺制药有限公司 Alk2激酶抑制剂
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
WO2024126617A1 (en) 2022-12-14 2024-06-20 Crossfire Oncology Holding B.V. Bifunctional compounds for degrading kinases via ubiquitin proteosome pathway
WO2024238570A1 (en) * 2023-05-15 2024-11-21 Aleksia Therapeutics, Inc. Cdk2 inhibitor pyrazolopyrimidine compounds
CN117756677B (zh) * 2023-12-21 2025-09-30 上海馨远医药科技有限公司 一种手性反式-n-boc-1-氨基环戊烷-3-甲酸的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504828A (ja) * 2001-10-02 2005-02-17 スミスクライン・ビーチャム・コーポレイション 化合物
JP2010516812A (ja) * 2007-01-30 2010-05-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 有糸分裂キナーゼの調節剤
WO2012098068A1 (en) * 2011-01-19 2012-07-26 F. Hoffmann-La Roche Ag Pyrazolo pyrimidines as dyrk1a and dyrk1b inhibitors
US20130345268A1 (en) * 2009-02-13 2013-12-26 The Trustees Of Dartmouth College Methods and Compositions for the Treatment of RAS Associated Disorders
JP2016510044A (ja) * 2013-03-05 2016-04-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌などの疾患の処置のためのトリアゾロ［４，５−ｄ］ピリミジン誘導体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
AU2014224976B2 (en) * 2013-03-05 2017-09-28 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504828A (ja) * 2001-10-02 2005-02-17 スミスクライン・ビーチャム・コーポレイション 化合物
JP2010516812A (ja) * 2007-01-30 2010-05-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 有糸分裂キナーゼの調節剤
JP2010532312A (ja) * 2007-01-30 2010-10-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド １−ｈ−ピラゾロ（３，４ｂ）ピリミジン誘導体および有糸分裂キナーゼの調節剤としてのその使用
US20130345268A1 (en) * 2009-02-13 2013-12-26 The Trustees Of Dartmouth College Methods and Compositions for the Treatment of RAS Associated Disorders
WO2012098068A1 (en) * 2011-01-19 2012-07-26 F. Hoffmann-La Roche Ag Pyrazolo pyrimidines as dyrk1a and dyrk1b inhibitors
JP2016510044A (ja) * 2013-03-05 2016-04-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌などの疾患の処置のためのトリアゾロ［４，５−ｄ］ピリミジン誘導体

Also Published As

Publication number Publication date
WO2019236631A1 (en) 2019-12-12
US20190375753A1 (en) 2019-12-12
TW202016112A (zh) 2020-05-01
US11046699B2 (en) 2021-06-29
EP3802544A1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
JP2021527051A (ja) ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
KR102566924B1 (ko) 케모카인 수용체 조절제 및 이의 용도
TWI826416B (zh) 趨化介素受體調節劑及其用途
JP6342805B2 (ja) 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
JP7003114B2 (ja) 統合ストレス経路のモジュレーター
TWI838350B (zh) 抗癌劑
JP7427655B2 (ja) 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法
JP6382831B2 (ja) アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
JP2021501785A (ja) 統合的ストレス経路の調節剤
JP2019108330A (ja) ｅＩＦ２α経路の調節因子
US20220305018A1 (en) Pyrazole pyrimidine compounds and uses thereof
JP2019511472A (ja) ヒストンメチルトランスフェラーゼ阻害剤
KR102275112B1 (ko) 5-브로모-인디루빈
CN111372927A (zh) 作为组蛋白甲基转移酶抑制剂的三环化合物
JP2025063134A (ja) 化学療法抵抗性がんの組合せ処置
KR20230118854A (ko) IRE1α 억제제 및 이의 용도
TW202406902A (zh) 趨化介素受體調節劑及其用途
TW201920165A (zh) 氮吲哚化合物作為組蛋白甲基轉移酶抑制劑
JP2023501584A (ja) Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用
CN116916900A (zh) 用于治疗膀胱癌的低氧诱导因子-2（α）抑制剂
CN115461054A (zh) 延伸因子1-α抑制剂及其用途
TW202233613A (zh) 去氧胞苷激酶抑制劑之結晶型及其用途
KR20230118855A (ko) IRE1α 억제제 및 이의 용도
US20250122208A1 (en) Chemokine receptor modulators and uses thereof
JP2023522980A (ja) Ｎｕｒｒ１受容体調節因子及びその使用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109